top of page
Browse by category
Search
D&D Pharmatech completes enrolment in trial evaluating DD01 Dual GLP-1/Glucagon receptor agonist for MASH
D&D Pharmatech has completed patient enrolment in DD01-DN-2, an ongoing Phase 2 trial designed to evaluate the efficacy and safety of...
ESSENCE trial: Semaglutide 2.4mg demonstrates statistically significant and superior improvements with in people with MASH
Results from part 1 of the ongoing Phase 3 ESSENCE trial - evaluating the effect of once-weekly subcutaneous semaglutide 2.4mg on liver...
FDA grants Breakthrough Therapy designation for Zealand Pharma’s survodutide
The FDA has granted Breakthrough Therapy designation to Zealand Pharma’s survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist...
Blocking circulating protein interferon-γ pathway could lead to potential treatment for metabolic liver disease
University of Massachusetts Medical School researchers have identified a novel pathway in the progression of metabolic liver disease that...
Journal Watch 12/06/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Tirzepatide was superior to placebo for MASH resolution
Results from Eli Lilly and Company’s SYNERGY-NASH that evaluated the investigational use of tirzepatide in adults with biopsy-proven...
Phase 2 trial shows 83% of adults treated with survodutide achieve significant improvement in MASH
Up to 83.0% of adults treated with survodutide (Boehringer Ingelheim and Zealand Pharma) achieved a statistically significant improvement...
Browse by tag
bottom of page